Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases

Cytokine

Volumn 69, Issue 1, 2014, Pages 62-67

  Maxeiner, Horst Guenter ^a   Marion Schneider, E ^c   Kurfiss, Sina Tatjana ^b   Brettschneider, Johannes ^b   Tumani, Hayrettin ^b   Bechter, Karl ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Rehabilitationskrankenhaus Ulm gGmbH   (Germany)

Author keywords

Affective and schizophrenic disorders; Cerebrospinal fluid; Multiplexed cytokine analysis; Neuroinflammation; Viral and bacterial meningitis

Indexed keywords

AGOMELATINE; AMISULPRIDE; AMITRIPTYLINE; ANTIINFECTIVE AGENT; ARIPIPRAZOLE; CHLORPROTHIXENE; CLOZAPINE; CYTOKINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; CELLULAR IMMUNITY; CYTOKINE BLOOD LEVEL; CYTOKINE BLOOD LEVEL CEREBROSPINAL FLUID LEVEL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIAL NERVE PARALYSIS; FEMALE; GAMMA INTERFERON BLOOD LEVEL; GAMMA INTERFERON CEREBROSPINAL FLUID LEVEL; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMUNOREGULATION; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 10 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 12P70 BLOOD LEVEL; INTERLEUKIN 12P70 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 13 BLOOD LEVEL; INTERLEUKIN 13 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 17 BLOOD LEVEL; INTERLEUKIN 17 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 1BETA BLOOD LEVEL; INTERLEUKIN 1BETA CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 2 BLOOD LEVEL; INTERLEUKIN 2 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 4 BLOOD LEVEL; INTERLEUKIN 4 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 5 BLOOD LEVEL; INTERLEUKIN 5 CEREBROSPINAL FLUID LEVEL; INTERLEUKIN 8 BLOOD LEVEL; INTERLEUKIN 8 CEREBROSPINAL FLUID LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHIZOPHRENIA; TENSION HEADACHE; TH2 CELL; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; TUMOR NECROSIS FACTOR ALPHA CEREBROSPINAL FLUID LEVEL; VIRUS MENINGITIS; BLOOD; CEREBROSPINAL FLUID; COMMUNICABLE DISEASES; IMMUNOLOGY; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

ADULT; COMMUNICABLE DISEASES; CYTOKINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

EID: 84901979336     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.008     Document Type: Article

References (41)

1. Mukaida N., Hishinuma A., Zachariae C.O., Oppenheim J.J., Matsushima K. Regulation of human interleukin 8 gene expression and binding of several other members of the intercrine family to receptors for interleukin-8. Adv Exp Med Biol 1991, 305:31-38.
2. Tal T.L., Simmons S.O., Silbajoris R., Dailey L., Cho S.H., Ramabhadran R., et al. Differential transcriptional regulation of IL-8 expression by human airway epithelial cells exposed to diesel exhaust particles. Toxicol Appl Pharmacol 2010, 243:46-54.
3. Fujita K., Matsui N., Takahashi Y., Iwasaki Y., Yoshida M., Yuasa T., et al. Increased interleukin-17 in the cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease: a case-control study of rapidly progressive dementia. J Neuroinflammat 2013, 10:135.
4. Bromander S., Anckarsater R., Kristiansson M., Blennow K., Zetterberg H., Anckarsater H., et al. Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J Neuroinflammat 2012, 9:242.
5. Stangel M., Fredrikson S., Meinl E., Petzold A., Stuve O., Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013, 9:267-276.
6. Sublette M.E., Russ M.J., Smith G.S. Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord 2004, 6:95-105.
7. Kuehne L.K., Reiber H., Bechter K., Hagberg L., Fuchs D. Cerebrospinal fluid neopterin is brain-derived and not associated with blood-CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. J Psychiatr Res 2013, 47:1417-1422.
8. Maxeiner H.G., Rojewski M.T., Schmitt A., Tumani H., Bechter K., Schmitt M. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun 2009, 23:134-142.
9. Bo S.H., Davidsen E.M., Gulbrandsen P., Dietrichs E., Bovim G., Stovner L.J., et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia 2009, 29:365-372.
10. Rozen T., Swidan S.Z. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache 2007, 47:1050-1055.
11. Liba Z., Kayserova J., Komarek V. Th1 and Th17 but no Th2-related cytokine spectrum in the cerebrospinal fluid of children with Borrelia-related facial nerve palsy. Fluids Barriers CNS 2013, 10:30.
12. Bechter K., Reiber H., Herzog S., Fuchs D., Tumani H., Maxeiner H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010, 44:321-330.
13. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotox Res 2011, 19:308-318.
14. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatr 2013, 18:595-606.
15. Maes M., Berk M., Goehler L., Song C., Anderson G., Galecki P., et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012, 10:66.
16. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006, 36:1357-1366.
17. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011, 11:221-230.
18. Woehrle T., Du W., Goetz A., Hsu H.Y., Joos T.O., Weiss M., et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008, 41:322-329.
19. Murray P.J., Smale S.T. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 2012, 13:916-924.
20. Abdelsadik A., Trad A. Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol 2011, 72:1188-1193.
21. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
22. Asano T., Ichiki K., Koizumi S., Kaizu K., Hatori T., Fujino O., et al. Enhanced expression of cytokines/chemokines in cerebrospinal fluids in mumps meningitis in children. Pediatr Int 2011, 53:143-146.
23. Prasad R., Kapoor R., Srivastava R., Mishra O.P., Singh T.B. Cerebrospinal fluid TNF-alpha, IL-6, and IL-8 in children with bacterial meningitis. Pediatr Neurol 2014, 50:60-65.
24. Ascherio A., Munger K.L., Lunemann J.D. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012, 8:602-612.
25. Tselis A. Evidence for viral etiology of multiple sclerosis. Semin Neurol 2011, 31:307-316.
26. Pakpoor J., Giovannoni G., Ramagopalan S.V. Epstein-Barr virus and multiple sclerosis: association or causation?. Expert Rev Neurother 2013, 13:287-297.
27. Kalinke U., Prinz M. Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. Immunol Cell Biol 2012, 90:505-509.
28. Mohammad M.G., Hassanpour M., Tsai V.W., Li H., Ruitenberg M.J., Booth D.W., et al. Dendritic cells and multiple sclerosis: disease, tolerance and therapy. Int J Mol Sci 2012, 14:547-562.
29. Tsai V.W., Mohammad M.G., Tolhurst O., Breit S.N., Sawchenko P.E., Brown D.A. CCAAT/enhancer binding protein-delta expression by dendritic cells regulates CNS autoimmune inflammatory disease. J Neurosci 2011, 31:17612-17621.
30. Bielekova B., Komori M., Xu Q., Reich D.S., Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 2012, 7:e48370.
31. Fragoso-Loyo H., Atisha-Fregoso Y., Llorente L., Sanchez-Guerrero J. Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatol (Oxford) 2013, 52:2218-2222.
32. Bechter K. Updating the mild encephalitis hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr 2013, 42:71-91.
33. Nikkila H.V., Ahokas A., Wahlbeck K., Rimon R., Andersson L.C. Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation. Neuropsychobiology 2002, 46:169-172.
34. Rapaport M.H., McAllister C.G., Pickar D., Tamarkin L., Kirch D.G., Paul S.M. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997, 25:123-129.
35. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatr 1995, 152:1291-1297.
36. Vawter M.P., Dillon-Carter O., Issa F., Wyatt R.J., Freed W.J. Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology 1997, 16:83-87.
37. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
38. Zhang X.Y., Zhou D.F., Qi L.Y., Chen S., Cao L.Y., Chen da C., et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacol (Berl) 2009, 204:177-184.
39. de Souza D.F., Wartchow K., Hansen F., Lunardi P., Guerra M.C., Nardin P., et al. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol Biol Psychiatr 2013, 43:14-22.
40. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatr 2011, 70:663-671.
41. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011, 12:13.